Investor Overview


Corporate Profile

Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within. Tocagen is currently studying its lead product candidate, Toca 511 & Toca FC, in a Phase 2/3 clinical trial for the treatment of patients with recurrent high grade glioma (HGG), a type of brain cancer with limited treatment options. Toca 511 & Toca FC has been granted Breakthrough Therapy Designation for the treatment of patients with recurrent HGG by the FDA.
NASDAQ GS TOCA (Common Stock)
$10.83 + 0.51
Stock chart for: TOCA.O.  Currently trading at $10.83 with a 52 week high of $17.95 and a 52 week low of $9.68.
07/24/17 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News

View All  

Tocagen Receives European Medicines Agency Priority Medicines (PRIME) Designation for Toca 511 in High Grade Glioma

07/24/17

Read More

Complementary Preclinical Studies Published in Neuro-Oncology Demonstrate Immune Activation Mechanism of Tocagen's Toca 511 & Toca FC

06/19/17

Read More

Tocagen Reports First Quarter 2017 Financial and Business Results

05/23/17

Read More

Recent Presentation

View All  
DateTitle
06/22/17
Download Documentation Corporate Presentation – June 20, 2017

Upcoming Events

View All  
There are currently no events scheduled.